UBS Group’s Stemline Therapeutics, Inc. STML Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q2 | – | Sell |
-37,627
| Closed | -$183K | – | 8675 |
|
|
2020
Q1 | $183K | Sell |
37,627
-22,465
| -37% | -$146K | ﹤0.01% | 4791 |
|
|
2019
Q4 | $639K | Sell |
60,092
-100,562
| -63% | -$998K | ﹤0.01% | 4618 |
|
|
2019
Q3 | $1.67M | Buy |
160,654
+82,154
| +105% | +$1.07M | ﹤0.01% | 3480 |
|
|
2019
Q2 | $1.2M | Buy |
78,500
+32,374
| +70% | +$468K | ﹤0.01% | 3601 |
|
|
2019
Q1 | $592K | Sell |
46,126
-60,488
| -57% | -$684K | ﹤0.01% | 3950 |
|
|
2018
Q4 | $1.01M | Buy |
106,614
+73,155
| +219% | +$949K | ﹤0.01% | 3675 |
|
|
2018
Q3 | $555K | Buy |
33,459
+9,506
| +40% | +$152K | ﹤0.01% | 4332 |
|
|
2018
Q2 | $385K | Sell |
23,953
-27,924
| -54% | -$498K | ﹤0.01% | 4510 |
|
|
2018
Q1 | $793K | Buy |
51,877
+40,304
| +348% | +$628K | ﹤0.01% | 3894 |
|
|
2017
Q4 | $181K | Buy |
11,573
+1,912
| +20% | +$25.6K | ﹤0.01% | 4990 |
|
|
2017
Q3 | $107K | Sell |
9,661
-15,698
| -62% | -$148K | ﹤0.01% | 5276 |
|
|
2017
Q2 | $234K | Sell |
25,359
-1,586
| -6% | -$13.2K | ﹤0.01% | 4656 |
|
|
2017
Q1 | $230K | Buy |
26,945
+15,232
| +130% | +$139K | ﹤0.01% | 4572 |
|
|
2016
Q4 | $126K | Buy |
11,713
+3,402
| +41% | +$41.1K | ﹤0.01% | 5132 |
|
|
2016
Q3 | $90K | Buy |
8,311
+811
| +11% | +$6.59K | ﹤0.01% | 5053 |
|
|
2016
Q2 | $51K | Hold |
7,500
| – | – | ﹤0.01% | 5514 |
|
|
2016
Q1 | $35K | Buy |
7,500
+486
| +7% | +$2.37K | ﹤0.01% | 5771 |
|
|
2015
Q4 | $44K | Buy |
7,014
+864
| +14% | +$7.01K | ﹤0.01% | 5934 |
|
|
2015
Q3 | $54K | Sell |
6,150
-2,300
| -27% | -$24.1K | ﹤0.01% | 5776 |
|
|
2015
Q2 | $99K | Buy |
8,450
+5,100
| +152% | +$70.8K | ﹤0.01% | 5416 |
|
|
2015
Q1 | $48K | Hold |
3,350
| – | – | ﹤0.01% | 6098 |
|
|
2014
Q4 | $57K | Buy |
+3,350
| New | +$48.3K | ﹤0.01% | 6334 |
|
UBS Group's STML Position: Q2 2020 in Review
UBS Group sold out of Stemline Therapeutics, Inc. (STML) in Q2 2020, closing a stake of 37,627 shares — an estimated $183K sold.
UBS Group first reported a position in STML in Q4 2014 and held it in 22 quarters. The position peaked at $1.67M in Q3 2019. 0 funds tracked by Wall St. Rank hold STML as of Q2 2020.
- UBS Group reported no remaining Stemline Therapeutics, Inc. position as of Q2 2020 after selling out during the quarter.
- UBS Group sold 37,627 Stemline Therapeutics, Inc. shares in Q2 2020, an estimated $183K.
- UBS Group first reported a position in Stemline Therapeutics, Inc. in Q4 2014 and held it in 22 quarters.
- UBS Group's Stemline Therapeutics, Inc. position peaked at $1.67M in Q3 2019.
- 0 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q2 2020.
Based on UBS Group's 13F filing for Q2 2020, filed 31 Jul 2020.